Effective Asthma Management: Is It Time to Let the AIR out of SABA?
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes. Instead, the more appropriate course is the use of a combined... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Journal of Clinical Medicine, Vol 9, Iss 4, p 921 (2020) |
Verlag/Hrsg.: |
MDPI AG
|
Schlagwörter: | SABA overuse / systemic steroid overuse / asthma control / mild asthma / ICS adherence / treatment / Medicine / R |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26894775 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3390/jcm9040921 |